DUBLIN--(BUSINESS WIRE)--The "Psoriasis Therapeutics Pipeline Analysis 2017" report has been added to Research and Markets' offering.
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development.
According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by topical route.
MC2 Therapeutics A/S is using PAD technology platform for the development of MC2-01 for the treatment of psoriasis. PAD technology platform offers a number of unique advantages in the development of new topical drugs. PAD vehicles are special made oil-in-water dispersions in which the internal oil phase is stabilized by encapsulation in a thin yet robust aqueous film of surfactants.
Various collaborations for psoriasis drug development:
- Boehringer Ingelheim GmbH and AbbVie, Inc. entered in a worldwide agreement to develop and commercialize BI 655066, for the treatment of psoriasis.
- Some of the key players developing drugs for the treatment of psoriasis include Amgen Inc., Maruho Co., Ltd., Boehringer Ingelheim GmbH and others.
Psoriasis Therapeutics Pipeline Analysis:
- By Phase
- By Molecule Type
- By Route of Administration
- By Company
Key Topics Covered:
1. Research Background
2. Research Methodology
3. Executive Summary
4. Pipeline Outlook
5. Psoriasis Therapeutics Pipeline Analysis by Phase (2017)
6. Clinical Trials Review
7. Competitive Landscape
8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/mjxm5f/psoriasis?w=4
